Banyan Biomarkers Inc., a company headquartered in Alachua, Fla. but with a growing presence in Carlsbad, has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott (NYSE: ABT) for assessment and verification. The terms of the agreement were not disclosed.
"Prior research has shown that protein markers are released in the bloodstream following a brain injury," said Jackson Streeter, CEO of Banyan Biomarkers. "Assessing these biomarkers is an important step forward in providing physicians with an objective test to evaluate patients who may have suffered a concussion."
Detecting concussions is often difficult because the physical damage may not be obvious. A CT scan is often normal and symptoms can be similar to those of other medical conditions. Failure to make a correct diagnosis may have serious implications for the patient. Research indicates that repetitive head injury may lead to chronic traumatic encephalopathy (CTE), which shares many features of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).